|
Report No. : |
322726 |
|
Report Date : |
18.05.2015 |
IDENTIFICATION DETAILS
|
Name : |
FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION |
|
|
|
|
Registered Office : |
2-2 Minatojima-Minamimachi Chuoku Kobe Hyogo-Pref 650-0047 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.03.2015 |
|
|
|
|
Date of Incorporation : |
March 2000 |
|
|
|
|
Com. Reg. No.: |
1400-05-020322 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Promote translational research (TR) on medical & medicine areas, other |
|
|
|
|
No of Employees : |
308 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
Yen 721.0 Million |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
JAPAN ECONOMIC OVERVIEW
In the years following World War II, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (1% of GDP) helped Japan develop a technologically advanced economy. Two notable characteristics of the post-war economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features are now eroding under the dual pressures of global competition and domestic demographic change. Since the complete shutdown of Japan’s nuclear reactors after the earthquake and tsunami disaster in 2011, Japan's industrial sector has become heavily dependent on imported raw materials and fuels. A small agricultural sector is highly subsidized and protected, with crop yields among the highest in the world. While self-sufficient in rice production, Japan imports about 60% of its food on a caloric basis. For three decades, overall real economic growth had been spectacular - a 10% average in the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the after effects of inefficient investment and an asset price bubble in the late 1980s that required a protracted period of time for firms to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession four times since 2008. A sharp downturn in business investment and global demand for Japan's exports in late 2008 pushed Japan into recession. Government stimulus spending helped the economy recover in late 2009 and 2010, but the economy contracted again in 2011 as the massive 9.0 magnitude earthquake and the ensuing tsunami in March disrupted manufacturing. A sales tax increase caused the economy to contract during the 2nd and 3rd quarters of 2014. The economy has largely recovered in the three years since the disaster, but reconstruction in the Tohoku region has been uneven due to labor shortages. Prime Minister Shinzo ABE has declared the economy his government's top priority; he has overturned his predecessor's plan to permanently close nuclear power plants and is pursuing an economic revitalization agenda of fiscal stimulus, monetary easing, and structural reform. Japan joined the Trans Pacific Partnership negotiations in 2013, a pact that would open Japan's economy to increased foreign competition and create new export opportunities for Japanese businesses. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, Japan in 2014 stood as the fourth-largest economy in the world after second-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. The government will continue a longstanding debate on restructuring the economy and reining in Japan's huge government debt, which amounts to more than 240% of GDP. To help raise government revenue and reduce public debt, Japan decided in 2013 to gradually increase the consumption tax to a total of 10% by 2015, although the government in 2014 decided to postpone the final phase of the increase until 2017 to give the economy time to recover from the 2014 increase. Japan is making progress on ending deflation due to a weaker yen and higher energy costs, but reliance on exports to drive growth and an aging, shrinking population pose other major long-term challenges for the economy.
|
Source
: CIA |
FOUNDATION
FOR BIOMEDICAL RESEARCH AND INNOVATION
Koeki Zaidan Hojin Sentan Iryo Shinko Zaidan
(Non-profit organization)
2-2 Minatojima-Minamimachi Chuoku Kobe Hyogo-Pref
650-0047 JAPAN
Tel: 078-306-1700 Fax: 078-306-1708
E-Mail address: zaidan-info@ibri-kobe.org
Promote translational research
(TR) on medical & medicine areas, other
Nil
HIROO IMURA, CHAIRMAN
Yen Amount: In million Yen, unless otherwise stated
FINANCES FAIR A/SALES Yen 7,896 M
PAYMENTSNO COMPLAINTS CAPITAL Yen
1,232 M*
TREND STEADY WORTH Yen 2,337 M
STARTED 2000 EMPLOYES 308
*.. Expressed by the Principal
Endowment figures
NON-PROFIT FOUNDATION FOR MEDICAL/MEDICINE, OTHER.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR PROPER
BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT: ESTIMATED AT
YEN 721.0 MILLION, ON 30 DAYS NORMAL TERMS.
This is a non-profit organization
(Foundation) established by the sponsorship of Hyogo-Pref, Kobe City and
private corporations for promoting translational research (TR) bridging basic
research and clinical application in three major areas: clinical application of
regenerative medicine, research & development of medical drugs and devices,
and support for clinical research & trials.
Promoting to achieve “Medical Industry of Kobe”.
The revenues for Mar/2014 fiscal
term amounted to Yen 7,896 million, a 3% down from
Yen
8,129 million in the previous term. The
net profit was posted at Yen 26 million, compared with Yen 14 million a year
ago.
For the term that ended Mar 2015 the
net profit was projected at Yen 30 million, on a 9% rise in turnover, to Yen
8,600 million. Final results are yet to
be released.
The financial situation is
considered FAIR and good for PROPER business engagements. Max credit limit is estimated at Yen 721.0
million, on 30 days normal terms.
Date Registered:
Mar 2000
Regd No.: 1400-05-020322
(Kobe-Chuoku)
Legal Status: Limited
Company (Kabushiki Kaisha)
Endowment: Yen
1,232.63 million
Major
shareholders (%): Hyogo-Pref, Kobe City, and 34 major
corporations
No. of
shareholders: 36
Nothing detrimental is known as
to the commercial morality of executives.
Activities:
Non-profit organization (Foundation) designed to promote translational research
(TR) bridging basic research and clinical application in the following three
major areas:
(1) Clinical application of regenerative medicine;
(2) Research and development of medical drugs and devices;
(3) Support for clinical research & trials, other
(--100%)
Clients:
Doctors, patients, corporations, other
No. of accounts: Unavailable
Domestic areas of activities:
Centered in Hyogo-Pref
Suppliers:
Corporations, individuals, other
Payment record: No Complaints
Location:
Business area in Kobe. Office premises
at the caption address are owned and maintained satisfactory.
Bank References:
SMBC
(Kobe)
Minato
Bank (H/O)
Relations:
Satisfactory
|
Terms Ending: |
|
31/03/2015 |
31/03/2014 |
31/03/2013 |
31/03/2012 |
|
Annual Sales |
|
8,600 |
7,896 |
8,129 |
7,894 |
|
Recur. Profit |
|
.. |
.. |
.. |
.. |
|
Net Profit |
|
30 |
26 |
14 |
64 |
|
Total Assets |
|
|
8,128 |
N/A |
N/A |
|
Net Worth |
|
|
2,337 |
2,311 |
2,297 |
|
Capital, Paid-Up |
|
|
1,234 |
--- |
--- |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
|
(%) |
(%) |
(%) |
(%) |
|
S.Growth Rate |
|
8.92 |
-2.87 |
2.98 |
-11.09 |
|
Current Ratio |
|
|
.. |
.. |
.. |
|
N.Worth Ratio |
|
|
28.75 |
.. |
.. |
|
N.Profit/Sales |
|
0.35 |
0.33 |
0.17 |
0.81 |
Notes: Financials are only
partially disclosed. Capital. Paid-Up is
expressed by the Endowment.
Forecast (or estimated) figures
for the 31/03/2015 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 63.57 |
|
|
1 |
Rs. 100.29 |
|
Euro |
1 |
Rs. 72.37 |
INFORMATION DETAILS
|
Analysis Done by
: |
KRN |
|
|
|
|
Report Prepared
by : |
DPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.